Published in J Immunol on September 15, 1998
Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med (1998) 2.30
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A (1999) 1.98
Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A (1999) 1.59
TLR9 regulates the mycobacteria-elicited pulmonary granulomatous immune response in mice through DC-derived Notch ligand delta-like 4. J Clin Invest (2008) 1.43
Transcutaneous immunization with combined cholera toxin and CpG adjuvant protects against Chlamydia muridarum genital tract infection. Infect Immun (2004) 1.30
Decreased TNF-alpha synthesis by macrophages restricts cutaneous immunosurveillance by memory CD4+ T cells during aging. J Exp Med (2009) 1.29
Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med (2005) 1.27
Immune mechanisms of protection: can adjuvants rise to the challenge? BMC Biol (2010) 1.22
Herpes simplex virus type 1 DNA is immunostimulatory in vitro and in vivo. J Virol (2003) 1.20
Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant. Infect Immun (2001) 1.19
Myd88-dependent in vivo maturation of splenic dendritic cells induced by Leishmania donovani and other Leishmania species. Infect Immun (2004) 1.14
Listeria monocytogenes-infected human dendritic cells: uptake and host cell response. Infect Immun (2000) 1.14
Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun (1999) 1.13
The immunogenicity and protective efficacy of bovine herpesvirus 1 glycoprotein D plus Emulsigen are increased by formulation with CpG oligodeoxynucleotides. J Virol (2002) 1.13
Protection against heterologous Burkholderia pseudomallei strains by dendritic cell immunization. Infect Immun (2006) 1.07
Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes. J Virol (2002) 1.06
CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies. Infect Immun (2000) 1.05
Dendritic cells induce immunity and long-lasting protection against blood-stage malaria despite an in vitro parasite-induced maturation defect. Infect Immun (2004) 1.02
A role for NF-kappaB-dependent gene transactivation in sunburn. J Clin Invest (2000) 1.01
Immunization onto bare skin with heat-labile enterotoxin of Escherichia coli enhances immune responses to coadministered protein and peptide antigens and protects mice against lethal toxin challenge. Immunology (2001) 1.00
Dendritic cells: immune saviors or Achilles' heel? Infect Immun (2001) 0.98
CpG-oligodeoxynucleotides enhance T-cell receptor-triggered interferon-gamma production and up-regulation of CD69 via induction of antigen-presenting cell-derived interferon type I and interleukin-12. Immunology (2000) 0.98
Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology (2007) 0.98
The effects of DNA containing CpG motif on dendritic cells. Immunology (2000) 0.96
Modulation of innate cytokine responses by products of Helicobacter pylori. Infect Immun (2000) 0.95
Phenotypic and functional alterations of dendritic cells induced by human herpesvirus 6 infection. J Virol (2002) 0.95
CpG-ODN-stimulated dendritic cells act as a potent adjuvant for E7 protein delivery to induce antigen-specific antitumour immunity in a HPV 16 E7-associated animal tumour model. Immunology (2004) 0.94
Discovery of novel immunostimulants by dendritic-cell-based functional screening. Blood (2005) 0.93
Molecular events of bacterial-induced maturation of dendritic cells. J Clin Immunol (2000) 0.92
CXCL10 is critical for the generation of protective CD8 T cell response induced by antigen pulsed CpG-ODN activated dendritic cells. PLoS One (2012) 0.91
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol (2012) 0.90
The linkage of innate and adaptive immune response during granulomatous development. Front Immunol (2013) 0.89
Cure of progressive murine leishmaniasis: interleukin 4 dominance is abolished by transient CD4(+) T cell depletion and T helper cell type 1-selective cytokine therapy. J Exp Med (1999) 0.89
Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology (2000) 0.89
Intranasal immunization of mice with a bovine respiratory syncytial virus vaccine induces superior immunity and protection compared to those by subcutaneous delivery or combinations of intranasal and subcutaneous prime-boost strategies. Clin Vaccine Immunol (2009) 0.88
Antipeptide antibody responses following intranasal immunization: effectiveness of mucosal adjuvants. Infect Immun (2000) 0.87
CpG oligodeoxynucleotides promote the host protective response against infection with Cryptococcus neoformans through induction of interferon-gamma production by CD4+ T cells. Clin Exp Immunol (2005) 0.86
Epigallocatechin-3-gallate suppresses proinflammatory cytokines and chemokines induced by Toll-like receptor 9 agonists in prostate cancer cells. J Inflamm Res (2014) 0.86
Effective induction of acquired resistance to Listeria monocytogenes by immunizing mice with in vivo-infected dendritic cells. Infect Immun (2003) 0.86
Inhibition of immunoglobulin E response to Japanese cedar pollen allergen (Cry j 1) in mice by DNA immunization: different outcomes dependent on the plasmid DNA inoculation method. Immunology (2000) 0.86
Oral pretreatment of mice with CpG DNA reduces susceptibility to oral or intraperitoneal challenge with virulent Listeria monocytogenes. Infect Immun (2003) 0.83
Protection of chickens against Escherichia coli infections by DNA containing CpG motifs. Infect Immun (2003) 0.83
CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol (2005) 0.82
Systemic administration of olygodeoxynucleotides with CpG motifs at priming phase reduces local Th2 response and late allergic rhinitis in BALB/c mice. Inflammation (2007) 0.82
Innate immune responses induced by CpG oligodeoxyribonucleotide stimulation of ovine blood mononuclear cells. Immunology (2003) 0.81
Intratumoral administration of secondary lymphoid chemokine and unmethylated cytosine-phosphorothioate-guanine oligodeoxynucleotide synergistically inhibits tumor growth in vivo. J Korean Med Sci (2011) 0.81
TLR9 mediates S. aureus killing inside osteoblasts via induction of oxidative stress. BMC Microbiol (2016) 0.80
Impact of microbes on autoimmune diseases. Arch Immunol Ther Exp (Warsz) (2013) 0.80
The arthritogenic and immunostimulatory properties of phosphorothioate oligodeoxynucleotides rely on synergy between the activities of the nuclease-resistant backbone and CpG motifs. Inflammation (2004) 0.80
Modulation of gene expression related to Toll-like receptor signaling in dendritic cells by poly(gamma-glutamic acid) nanoparticles. Clin Vaccine Immunol (2010) 0.79
Mucosal immunization with helicobacter, CpG DNA, and cholera toxin is protective. Infect Immun (2003) 0.79
Local therapy with CpG motifs in a murine model of allergic airway inflammation in IFN-beta knock-out mice. Respir Res (2005) 0.79
A combination hydrogel microparticle-based vaccine prevents type 1 diabetes in non-obese diabetic mice. Sci Rep (2015) 0.78
Molecular mechanism of immune response induced by foreign plasmid DNA after oral administration in mice. World J Gastroenterol (2007) 0.78
A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets. Mediators Inflamm (2016) 0.78
Gene expression profiling of dendritic cells reveals important mechanisms associated with predisposition to Staphylococcus infections. PLoS One (2011) 0.77
Prevention of human adenocarcinoma with CpG-ODN in a mouse model. Oncol Lett (2012) 0.77
Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides. J Clin Immunol (2003) 0.77
Interleukin-17A is involved in development of spontaneous pulmonary emphysema caused by Toll-like receptor 4 mutation. Acta Pharmacol Sin (2011) 0.77
CpG oligodeoxynucleotides accelerate reovirus type 2-triggered insulitis in DBA/1 suckling mice. Int J Exp Pathol (2002) 0.76
Daedalic DNA vaccination against self antigens as a treatment for chronic kidney disease. Int J Clin Exp Pathol (2013) 0.75
Efficacy of dendritic cells matured early with OK-432 (Picibanil), prostaglandin E2, and interferon-alpha as a vaccine for a hormone refractory prostate cancer cell line. J Korean Med Sci (2010) 0.75
Murine J774 macrophages recognize LPS/IFN-g, non-CpG DNA or two-CpG DNA-containing sequences as immunologically distinct. Nitric Oxide (2010) 0.75
CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc Natl Acad Sci U S A (1996) 5.26
"Boosted lubrication" in synovial joints by fluid entrapment and enrichment. Ann Rheum Dis (1968) 4.42
CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med (1997) 4.06
Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol (2001) 3.64
The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J Exp Med (2001) 3.63
Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 3.34
The role of the menisci in force transmission across the knee. Clin Orthop Relat Res (1975) 3.24
CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J Immunol (1998) 2.93
Normal and abnormal motion of the shoulder. J Bone Joint Surg Am (1976) 2.87
Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 2.74
Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 2.73
A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells. J Exp Med (1996) 2.72
Adhesion of epidermal Langerhans cells to keratinocytes mediated by E-cadherin. Nature (1993) 2.68
Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol (2000) 2.59
Behaviour of synovial fluid on surfaces of articular cartilage. A scanning electron microscope study. Ann Rheum Dis (1969) 2.53
Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A (1997) 2.35
Aseptic loosening in cemented custom-made prosthetic replacements for bone tumours of the lower limb. J Bone Joint Surg Br (1996) 2.32
Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity. J Exp Med (1998) 2.30
Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol (1993) 2.20
An essential role for Langerhans cell-derived IL-1 beta in the initiation of primary immune responses in skin. J Immunol (1993) 2.17
Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. J Immunol (1996) 2.06
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol (2004) 1.98
CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc Natl Acad Sci U S A (1999) 1.98
Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol (1998) 1.97
Negative control region at the 5' end of murine leukemia virus long terminal repeats. Mol Cell Biol (1989) 1.88
Endoprosthetic replacement of the proximal tibia. J Bone Joint Surg Br (1999) 1.82
Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther (1998) 1.76
CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest (1997) 1.71
Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. Vaccine (2004) 1.71
CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. Proc Natl Acad Sci U S A (1998) 1.70
Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol (2001) 1.65
CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol (1998) 1.62
Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. Semin Arthritis Rheum (1999) 1.59
Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. Proc Natl Acad Sci U S A (1999) 1.59
Interleukin-12- and gamma interferon-dependent protection against malaria conferred by CpG oligodeoxynucleotide in mice. Infect Immun (2001) 1.55
Forces at the glenohumeral joint in abduction. Clin Orthop Relat Res (1978) 1.54
Mechanical evaluation of mobile bearing knees. Am J Knee Surg (1997) 1.51
Control of cement penetration in total knee arthroplasty. Clin Orthop Relat Res (1984) 1.50
Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol (1997) 1.46
Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. J Immunol (1996) 1.46
Expression of gp40, the murine homologue of human epithelial cell adhesion molecule (Ep-CAM), by murine dendritic cells. Eur J Immunol (1996) 1.44
Ligament length patterns, strength, and rotational axes of the knee joint. Clin Orthop Relat Res (1976) 1.39
Rudimentary meningocele presenting with a scalp hair tuft. Report of two cases. Arch Dermatol (1994) 1.38
The forces in the distal femur and the knee during walking and other activities measured by telemetry. J Arthroplasty (1998) 1.37
Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis. Eur J Immunol (2000) 1.36
Polyploidy, phylogeography and Pleistocene refugia of the rockfern Asplenium ceterach: evidence from chloroplast DNA. Mol Ecol (2002) 1.36
A role for TGFbeta1 in langerhans cell biology. Further characterization of the epidermal Langerhans cell defect in TGFbeta1 null mice. J Clin Invest (1997) 1.35
CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. Vaccine (1998) 1.35
CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. Antisense Nucleic Acid Drug Dev (2001) 1.34
Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 1.34
Inhalant use among urban American Indian youth. Addiction (1999) 1.34
CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J Immunol (1998) 1.34
Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. J Immunol (1998) 1.33
Regulation of E-cadherin-mediated adhesion in Langerhans cell-like dendritic cells by inflammatory mediators that mobilize Langerhans cells in vivo. J Immunol (1998) 1.33
The dominance of cyclic sliding in producing wear in total knee replacements. Clin Orthop Relat Res (1991) 1.31
CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol (2001) 1.30
"Boosted lubrication" of human joints by fluid enrichment and entrapment. Biomed Eng (1969) 1.29
Enhanced dendritic cell maturation by TNF-alpha or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J Immunol (2000) 1.29
Variations in strength and structure of cancellous bone at the knee. J Biomech (1974) 1.28
CpG DNA induces maturation of dendritic cells with distinct effects on nascent and recycling MHC-II antigen-processing mechanisms. J Immunol (2000) 1.27
Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. Antisense Res Dev (1994) 1.27
Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? Antisense Res Dev (1995) 1.26
Influence of muscle activity on the forces in the femur: an in vivo study. J Biomech (1998) 1.22
IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J Immunol (1996) 1.21
Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine (1999) 1.20
The use of hydroxyapatite-coated CAD-CAM femoral components in adolescents and young adults with inflammatory polyarthropathy: ten-year results. J Bone Joint Surg Br (2006) 1.20
CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. J Immunol (1999) 1.19
CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev (2001) 1.19
Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res Dev (1993) 1.19
CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. J Immunol (1996) 1.18
Distal femoral arthroplasty using custom-made prostheses. The first 218 cases. J Arthroplasty (1993) 1.17
CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 1.15
Multistep navigation of Langerhans/dendritic cells in and out of the skin. J Allergy Clin Immunol (2001) 1.15
Expression of naked DNA in human, pig, and mouse skin. J Clin Invest (1996) 1.15
Cementless fixation for primary segmental bone tumor endoprostheses. Clin Orthop Relat Res (2000) 1.14
Tibial component fixation in deficient tibial bone stock. Clin Orthop Relat Res (1984) 1.14
Inhibition of epidermal Langerhans cell function by low dose ultraviolet B radiation. Ultraviolet B radiation selectively modulates ICAM-1 (CD54) expression by murine Langerhans cells. J Immunol (1991) 1.13
Cytokine gene expression in epidermis with biological effects following injection of naked DNA. Nat Genet (1995) 1.13
Alcohol abuse in urban Indian adolescents and women: a longitudinal study for assessment and risk evaluation. Am Indian Alsk Native Ment Health Res (1996) 1.12
Forces and moments telemetered from two distal femoral replacements during various activities. J Biomech (2001) 1.11
Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol (2006) 1.11
Attachment and proliferation of osteoblasts and fibroblasts on biomaterials for orthopaedic use. Biomaterials (1995) 1.11
Stabilizing mechanisms of the loaded and unloaded knee joint. J Bone Joint Surg Am (1976) 1.10
The load-bearing area in the knee joint. J Biomech (1972) 1.10
Human Langerhans cells express E-cadherin. J Invest Dermatol (1995) 1.09
Properties of neurons from dissociated fetal rat brain in serum-free culture. J Neurosci (1983) 1.09
Effect of knee component alignment on tibial load distribution with clinical correlation. Clin Orthop Relat Res (1989) 1.08
Geometry and motion of the knee for implant and orthotic design. J Biomech (1985) 1.08
Extracellular domain of pemphigus vulgaris antigen (desmoglein 3) mediates weak homophilic adhesion. J Invest Dermatol (1994) 1.07
Murine epidermal label-retaining cells isolated by flow cytometry do not express the stem cell markers CD34, Sca-1, or Flk-1. J Invest Dermatol (2001) 1.06
Now I know my CpGs. Trends Microbiol (2001) 1.06
The Gerbich blood group system: a review. Immunohematology (2010) 1.06
NIH conference. Systemic lupus erythematosus. Ann Intern Med (1991) 1.06